Explore the vast range of titles available.

Examine the social and cultural impact of basketball on America at the amateur and professional levels! Basketball in America: From the Playgrounds to Jordan's Game and Beyond is a pioneering analysis of the history of basketball and its effect on popular culture from the 1970s to today. The popularity of basketball is undeniable, and the subject allows for such a broad range of interpretations in popular culture. It cuts across economic, racial, and social boundaries, and its major stars cross over into other forms of popular entertainment more than any other professional sport. This book examines the entire scope of modern basketball history, from the playgrounds, where people first learn the fundamentals, to the college and professional levels. Basketball in America is a collection of essays that explores the intersection of basketball and popular culture in America. The contributors are an eclectic mix of writers, scholars, journalists, former players, coaches, and sports enthusiasts who all share an undying love for the game of basketball. The authors analyze the sport from a cross-cultural and historical perspective-digging deep into the profound popular cultural influences of basketball and exploring the scope and depth of its influence. This is the first book that examines the social and cultural impact of basketball on American society to reveal how tightly it is woven into America's cultural fabric. Also included are photographs and tables to enhance your understanding of the material. Topics covered in Basketball in America include: Elgin Baylor-the first “modern” basketball player Chocolate Thunder and Short Shorts: The NBA in the 1970s Dr. J, Bird, Magic, Jordan, and the Bad Boys: The NBA in the 1980s The Jordan Era: The NBA in the 1990s LeBron James and the future of the NBA the Nike brand and popular culture lesso

Basketball in America is a collection of essays that explores the intersection of the sport and popular cultures in modern America-as we have defined it-since the 1970s. Our goal is to examine basketball from a cross-cultural and historical perspective to reveal how tightly the game is now wound into American (and by extension, global) popular culture and society.

The epidermal growth factor receptor, EGFR, is frequently activated in lung cancer and glioblastoma by genomic alterations including missense mutations. The different mutation spectra in these diseases are reflected in divergent responses to EGFR inhibition: significant patient benefit in lung cancer, but limited in glioblastoma. Here, we report a comprehensive mutational analysis of EGFR function. We perform saturation mutagenesis of EGFR and assess function of ~22,500 variants in a human EGFR-dependent lung cancer cell line. This approach reveals enrichment of erlotinib-insensitive variants of known and unknown significance in the dimerization, transmembrane, and kinase domains. Multiple EGFR extracellular domain variants, not associated with approved targeted therapies, are sensitive to afatinib and dacomitinib in vitro. Two glioblastoma patients with somatic EGFR G598V dimerization domain mutations show responses to dacomitinib treatment followed by within-pathway resistance mutation in one case. In summary, this comprehensive screen expands the landscape of functional EGFR variants and suggests broader clinical investigation of EGFR inhibition for cancers harboring extracellular domain mutations. EGFR mutations are frequent in glioblastoma and lung cancer. Here, the authors perform deep mutational scanning of EGFR, followed by a high-throughput functional screen and analysis of patient data, to identify variants with differing sensitivities to a range of EGFR tyrosine kinase inhibitors.

Glioblastoma is immunologically “cold” and resistant to single-agent immune-checkpoint inhibitors (ICI). Our previous study of neoadjuvant pembrolizumab in surgically-accessible recurrent glioblastoma identified a molecular signature of response to ICI and suggested that neoadjuvant pembrolizumab may improve survival. To increase the power of this observation, we enrolled an additional 25 patients with a primary endpoint of evaluating the cell cycle gene signature associated with neoadjuvant pembrolizumab and performed bulk-RNA seq on resected tumor tissue (NCT02852655). Neoadjuvant pembrolizumab was associated with suppression of cell cycle/cancer proliferation genes and upregulation of T-cell/interferon-related gene expression. This signature was unique to patients treated with neoadjuvant pembrolizumab and was an independent positive risk factor for survival. Our results demonstrate a clear pharmacodynamic effect of anti-PD1 therapy in glioblastoma and identify pathways that may mediate resistance. However, we did not confirm a survival benefit to neoadjuvant pembrolizumab in recurrent glioblastoma and our secondary endpoint of PFS-6 was 19.5% (95% CI: 9.29-41.2%) for the pooled neoadjuvant cohorts. Our new data suggests some patients may exhibit innate resistance to pre-surgical ICI and require other concomitant therapies to sensitize effectively. Glioblastoma is resistant to immune-checkpoint inhibitors. In this study, the authors report the results of an expansion cohort (n = 25) of a randomized testing neoadjuvant plus adjuvant pembrolizumab versus adjuvant pembrolizumab alone in patients with recurrent glioblastoma with resectable tumors.